On July 17, a briefing was held on Capitol Hill to provide information to legislators on the importance of expanding the use and availability of radiopharmaceuticals. In 2008, Medicare grouped radiopharmaceuticals as consumables which bundled them into the payment for the procedure. This has resulted in restricting the development and use of these radiopharmaceuticals. The bill, HR 3772, the Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019, aims to rectify the situation which will result in broader access and further development of disease specific radiopharmaceuticals.